Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models
Antony J Williams John Wilbanks Sean Ekins
Chapter from the book: Moore, S. 2014. Issues in Open Research Data.
Part of
Chapter from the book: Moore, S. 2014. Issues in Open Research Data.
First paragraph: Public online databases supporting life sciences research have become valuable resources for researchers depending on data for use in cheminformatics, bioinformatics, systems biology, translational medicine, and drug repositioning efforts, to name just a few of the potential end user groups (Williams et al. 2009). Worldwide funding agencies (governments and not-for-profits) have invested in public domain chemistry platforms. In the United States these include PubChem, ChemIDPlus, and the Environmental Protection Agency’s ACToR, while the United Kingdom has funded ChEMBL and ChemSpider, among others, and new databases continue to appear annually (National Center for Biotechnology Information, n.d.; US National Library of Medicine, n.d.; Judson et al. 2008; EMBL-EBI, n.d.; Pence & Williams 2010; Galperin & Cochrane 2011).
Williams, A et al. 2014. Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models. In: Moore, S (ed.), Issues in Open Research Data. London: Ubiquity Press. DOI: https://doi.org/10.5334/ban.e
This is an Open Access chapter distributed under the terms of the Creative Commons Attribution 4.0 license (unless stated otherwise), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. Copyright is retained by the author(s).
This book has been peer reviewed. See our Peer Review Policies for more information.
Published on Dec. 19, 2014